Engineered CMV gB Proteins for Environmental Monitoring and Control

Publication ID: 24-11857622_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Engineered CMV gB Proteins for Environmental Monitoring and Control,” Published Technical Disclosure No. 24-11857622_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857622_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,622.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of engineered mutant cytomegalovirus glycoprotein B (gB) proteins to develop novel systems and methods for monitoring and controlling environmental threats, such as crop diseases, invasive species, water pollutants, pest populations, and wildfires.

Background and Problem Solved

The original patent disclosed engineered mutant CMV gB proteins with improved stability and binding properties. However, the patent's scope was limited to human cytomegalovirus and its applications. The present inventive concept addresses the need for innovative solutions in environmental monitoring and control, where current methods are often inadequate, expensive, or invasive.

Detailed Description of the Inventive Concept

The new claims describe systems and methods that utilize engineered mutant CMV gB proteins modified to bind specifically to various environmental targets, such as disease-causing pathogens, invasive species, pollutants, pests, or fire-related chemicals. These proteins provide a detectable signal upon binding, enabling real-time monitoring and control of environmental threats. The inventive concept encompasses a range of applications, including crop disease monitoring, invasive species tracking, water pollution detection, pest population control, and wildfire detection.

Novelty and Inventive Step

The new claims introduce a paradigm shift by applying the core technology of engineered mutant CMV gB proteins to entirely new fields, including environmental monitoring and control. This inventive step lies in the unexpected use of these proteins to address pressing environmental challenges, demonstrating a non-obvious connection between the original patent's technology and these novel applications.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different protein modifications, such as fluorescent or magnetic labels, to enhance detection capabilities. Variations may also involve the development of portable or handheld devices for in-field monitoring, or the integration of machine learning algorithms to improve predictive capabilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including agriculture, environmental consulting, water treatment, pest control, and firefighting. The market for environmental monitoring and control systems is growing rapidly, driven by increasing concerns about climate change, sustainability, and public health.

CPC Classifications

SectionClassGroup
A A61 A61K39/245
C C07 C07K14/045
C C12 C12N7/00
C C12 C12N2710/16134

Field of Art

Molecular virology, protein engineering, and biotechnology with a focus on cytomegalovirus glycoprotein modification and functional adaptation

Person of Ordinary Skill (PHOSITA) Profile

A molecular biologist or protein engineer with expertise in viral protein structure, mutation techniques, and biotechnological applications, holding at least a PhD or equivalent industrial experience in protein design and functional modification

Obviousness Rationale

A skilled practitioner would recognize the inherent adaptability of engineered CMV gB proteins for diverse binding and signaling applications. The source patent establishes a foundational technology of mutant glycoprotein B with enhanced stability and structural modifications. Given the protein's demonstrated capacity for precise engineering and targeted mutations, extending its utility to environmental monitoring represents a predictable and logical technological progression.

Obvious Combinations & Variations

Source Patent Element
Engineered mutant CMV gB protein with specific amino acid mutations
PTD Variation
Modifying protein to bind specific environmental targets like pathogens or pollutants
Obviousness Reasoning
Protein engineering techniques for creating binding specificity are well-established, and the source patent demonstrates the protein's structural malleability
Source Patent Element
Prefusion-specific stability measurements via antibody binding and thermal shift assay
PTD Variation
Adding detection mechanisms like fluorescent or magnetic labels for environmental monitoring
Obviousness Reasoning
Incorporating additional detection modalities represents a routine design choice for a skilled protein engineer seeking expanded functional capabilities
Source Patent Element
Trimer configuration of mutant glycoprotein B
PTD Variation
Adapting protein configuration for specific binding interactions in environmental sensing applications
Obviousness Reasoning
Structural modifications to optimize protein binding are predictable outcomes of rational protein design approaches
Source Patent Element
Mutations derived from Towne strain CMV gB sequence
PTD Variation
Extending mutation strategies to create species-specific or target-specific binding proteins
Obviousness Reasoning
Sequence-based protein engineering is a standard technique for creating targeted molecular recognition tools
Source Patent Element
Disulfide mutation strategies for protein stabilization
PTD Variation
Applying similar mutation techniques to create environmentally robust protein sensors
Obviousness Reasoning
Protein stabilization strategies are directly transferable across different application domains using established molecular engineering principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857622, a person having ordinary skill in the art would find the environmental monitoring applications of engineered CMV gB proteins to be obvious variations of the foundational protein modification techniques disclosed in the source patent. The predictable extension of protein engineering principles to novel sensing and detection applications renders subsequent claims involving such technologies unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,622
TitleHuman cytomegalovirus GB polypeptide
Assignee(s)Pfizer Inc.